Advances in imaging: Target delineation

Cancer Journal

Volumn 17, Issue 3, 2011, Pages 151-154

  Hunter, Klaudia U ^a   Eisbruch, Avraham ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

dynamic contrast enhanced MRI; FDG PET; Methionine PET

Indexed keywords

FLUORODEOXYGLUCOSE F 18; METHIONINE;

BRAIN TUMOR; CANCER RADIOTHERAPY; HEAD AND NECK CANCER; HUMAN; LUNG CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW;

DIAGNOSTIC IMAGING; HUMANS; MAGNETIC RESONANCE IMAGING; NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79958806459     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e31821d7e35     Document Type: Review

References (27)

1. 18F-fluoromisonidazole PET in newly diagnosed glioblastoma. Eur J Nucl Med Mol Imaging. 38:441-450.
2. 11C]methionine positron emission tomography for target definition of glioblastoma multiforme in radiation therapy planning. [Published online ahead of print November 20, 2010.] Int J Radiat Oncol Biol Phys.
3. 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy. J Nucl Med. 2008;49:694-699.
4. Herholz K, Holzer T, Bauer B, et al. 11C-methionine PET for differential diagnosis of low-grade gliomas. Neurology. 1998;50:1316-1322. (Pubitemid 28240345)
5. 11C methionine positron emission tomography (PET) data - results of a pilot study in 32 surgical cases. ActaNeurochir. 2002;144:777-782.
6. 11C-methionine PET in the evaluation of brain lesions that are hypo- or isometabolic on 18-FDG PET. Eur J Nucl Med Mol Imaging. 2002;29:176-182.
7. 11C]L-methionine positron emission tomography: local comparison with stereotactic histopathology. Clin Cancer Res. 2004;10:7163-7170.
8. Okamoto S, Shiga T, Hattori N, et al. Semiquantitative analysis of C-11 methionine PET may distinguish brain tumor recurrence from radiation necrosis even in small lesions. Ann Nucl Med. 2010;25:213-220.
9. Beppu T, Sasaki M, Kudo K, et al. Prediction of malignancy grading using computed tomography perfusion imaging in nonenhancing supratentorial gliomas. [Published online ahead of print October 15, 2010.] J Neurooncol. 2010.
10. 11C-methionine PET and perfusion MRI. Clin Neurol Neurosurg. 2010;112:758-765.
11. Jain R, Narang J, Schultz L, et al. Permeability estimates in histopathology-proved treatment-induced necrosis using perfusion CT: can these add to other perfusion parameters in differentiating from recurrent/progressive tumors? AJNR Am J Neuroradiol. 2011;32:658-663.
12. Misono S, Rue T, Rajendran J, Davis GE. Effects of upstaging from PET scan on survival in head and neck squamous cell carcinoma. Head Neck. 2010;32:1283-1287.
13. Joshi U, van der Hoeven JJ, Comans EF, et al. In search of an unknown primary tumor presenting with extra-cervical metastases: the diagnostic performance of FDG-PET. Br J Radiol. 2004;77:1000-1006.
14. 18F- fluorodeoxyglucose for staging of non-small cell lung cancer. Nuklearmedizin. 2003;42:135-144.
15. Bradley J, Thorstad WL, Mutic S, et al. Impact of FDG-PET on radiation therapy volume delineation in NSCLC. Int J Radiat Oncol Biol Phys. 2004;59:78-86. (Pubitemid 38501510)
16. van Tinteren H, Hoekstra OS, Smit EF, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet. 2002;359:1388-1393.
17. 18F- deoxyglucose (FDG) image fusion for optimization of conformal radiotherapy of lung cancers. Int J Radiat Oncol Biol Phys. 2001;49:1249-1257.
18. 18FDG-PET on target and critical organs in CT-based treatment planning of patients with poorly defined non-small-cell lung carcinoma: a prospective study. Int J Radiat Oncol Biol Phys. 2002;52:339-350.
19. Erdi YE, Rosenzweig K, Erdi AK, et al. Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography (PET). Radiother Oncol. 2002;62:51-60. (Pubitemid 34121949)
20. Ciernik IF, Dizendort E, Baumert BG, et al. Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): a feasibility study. Int J Radiat Oncol Biol Phys. 2003;57:853-863. (Pubitemid 37194314)
21. D'Souza WD, Nazareth DP, Zhang B, et al. The use of gated and 4D CT imaging in planning for stereotactic body radiation therapy. Med Dosim. 2007;32:92-101. (Pubitemid 46654806)
22. Fiorno C, Reni M, Bolgnesi A, et al. Intra- and inter-observer variability in contouring prostate and seminal vesicles: implications for conformal treatment planning. Radiother Oncol. 1998;47:285-292. (Pubitemid 28293650)
23. McLaughlin PW, Evans C, Feng M, et al. Radiographic and anatomic basis for prostate contouring errors and methods to improve prostate contouring accuracy. Int J Radiat Oncol Biol Phys. 2010;76:369-378.
24. Kitajima K, Kaji Y, Fukabori Y, et al. Prostate cancer detection with 3 T MRI: comparison of diffusion-weighted imaging and dynamic contrast-enhanced MRI in combination with T2-weighted imaging. J Magn Reson Imaging. 2010;31:625-631.
25. Langer DL, van der Kwast TH, Evans AJ, et al. Prostate cancer detection with multi-parametric MRI: logistic regression analysis of quantitative T2, diffusion-weighted imaging, and dynamic contrast-enhanced MRI. J Magn Reson Imaging. 2009;30:327-334.
26. Kozlowski P, Chang SD, Meng R, et al. Combined prostate diffusion tensor imaging and dynamic contrast enhanced MRI at 3 T - quantitative correlation with biopsy. Magn Reson Imaging. 2010;28:621-628.
27. McLaughlin PW, Narayana V, Drake DG, et al. Comparison of MRI pulse sequences in defining prostate volume after permanent implantation. Int J Radiat Oncol Biol Phys. 2002;54:703-711.